In three samples tested CD34+CLL‐1+ AML cells were indeed able to engraft and generate CLL‐1+ blasts in immunodeficient mice.10 Thus, CLL‐1 has emerged as an attractive target for antibody‐ or CAR T‐cell‐based therapeutics.11, 12 However, we found that CLL‐1 expression was lower in the LSC‐enriched CD34+CD38− compartment and inversely correlated with the LSC gene signature in CD34‐positive AML samples. Here, CLEC12A is linked to acute myeloid leukemia.